Rundu Pharma(SZ:002923)2025-09-09 08:18Company Overview - Zhuhai Rundu Pharmaceutical Co., Ltd. was established in 1999 and listed on the Shenzhen Stock Exchange in January 2018 [2] - The company focuses on the research, production, and sales of chemical drug formulations, raw materials, and intermediates, covering various therapeutic areas [2] Business Performance - In the first half of 2025, the company's other business segments, including CMO and CDMO, achieved a year-on-year growth of 196.89%, with revenue reaching 6.58 million yuan [3] - The nicotine products from Jingmen Company are classified under raw material manufacturing, with significant sales growth, although it has not yet impacted overall performance [3] Regulatory and Product Development - The company’s innovative drug, the hydrochloride injection of dextromethorphan, had its registration application accepted in March 2024, with ongoing review processes [4] Financial Challenges - The net profit for raw materials and intermediates declined due to a significant drop in raw material prices, despite stable sales revenue [5][6] - The formulation business faced a decrease in net profit due to the impact of national procurement policies and a drop in sales of key products like rabeprazole sodium enteric-coated capsules [6]